Literature DB >> 22469427

L-index as a novel index to evaluate both the intensity and duration of lymphopenia after allogeneic hematopoietic stem cell transplantation.

S-I Kimura1, H Wada, K Sakamoto, M Ashizawa, M Sato, K Terasako, H Nakasone, M Kikuchi, S Okuda, S Kako, R Yamazaki, K Oshima, Y Tanaka, A Tanihara, J Nishida, Y Kanda.   

Abstract

We retrospectively investigated L-index, which evaluates both the intensity and duration of lymphopenia after allogeneic hematopoietic stem cell transplantation (HSCT) (n = 50). L-index was defined as the area over the lymphocyte curve during lymphopenia (absolute lymphocyte count < 700/μL). We calculated the L-index from the start of conditioning to day 30 - L-index(30) - and to day 100 - L-index(100) - after HSCT. Multivariate analysis revealed that human leukocyte antigen mismatched donor, female gender, and non-lymphoid disease were significantly associated with high L-index(30). Grade III-IV acute graft-versus-host disease, alemtuzumab-containing regimen, and non-lymphoid disease were identified as independent significant factors for high L-index(100). Cytomegalovirus (CMV) antigenemia was detected > 3 cells/2 slides by C10/11 method in 30 patients (CMV-AG ≥ 3 group) and was not detected in 20 patients (CMV-AG < 3 group). Although no significant difference was seen in absolute lymphocyte count on day 30 between the 2 groups, the L-index(30) was significantly higher in the CMV-AG ≥ 3 group than in the CMV-AG < 3 group (P = 0.050). L-index(30) was identified as an independent factor on CMV reactivation in multivariate analysis, when it was treated as a dichotomous variable with a cut-off value of 22,318, determined by receiver operating characteristic curve analysis. In conclusion, both the intensity and duration of lymphopenia in early phase after HSCT evaluated on the basis of L-index(30) showed significant association with CMV reactivation.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2012        PMID: 22469427     DOI: 10.1111/j.1399-3062.2012.00727.x

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  1 in total

1.  Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy<sup/>.

Authors:  Jason N Barreto; Kristen B McCullough; Candy S Peskey; Ross A Dierkhising; Kristin C Mara; Michelle A Elliott; Dennis A Gastineau; Aref Al-Kali; Naseema Gangat; Louis Letendre; William J Hogan; Mark R Litzow; Mrinal M Patnaik
Journal:  Leuk Lymphoma       Date:  2017-05-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.